glp-1 drugs for parkinson's disease receptor agonists show promise in treating substance use disorders GLP-1 Receptor Agonists: A New

GLP-1 agonist drugs, often called GLP-1s, are injectable medications that work by mimicking the GLP-1 hormone that your small intestine makes in response to food

Whether GLP-1/GIP drugs can impact fibrosis remains an open basic and clinical question

Read More GLP-1 Drugs and Parkinsons Disease: Could Metabolic Therapy Influence Neurodegeneration

Back WHO (1 March 2024) 'Obesity and overweight', WHO News

By 2035, oral formulations will expand the overall market by targeting new, hitherto unaddressed patient populations rather than taking significant share from existing injectables

Providers should be aware of the individual experience of their patients with these drugs and critically assess the unique health factors that impact outcomes when patients utilize this class of drugs